VCANBIO: VUM02 injection for the treatment of active moderate to severe ulcerative colitis clinical trial approved
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, VCANBIO announced that its wholly-owned subsidiary Wuhan Guanggu VCANBIO Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration on December 16 for the use of VUM02 injection in the treatment of active moderate to severe ulcerative colitis
According to the Zhitong Finance APP, VCANBIO (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu VCANBIO Pharmaceutical Co., Ltd., received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration on December 16th for the use of VUM02 injection in the treatment of active moderate to severe ulcerative colitis